Gene therapy for hereditary spastic paraplegia hits proof-of-principle milestone

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College of Medicine and the UMass Chan Medical School have achieved proof-of-principle success with “silence and replace” gene therapy—an approach that uses a viral vector to silence genes with disease-causing mutations and replace them with healthy genes—to prevent and even reverse disease progression.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup